Publications by authors named "Kunihide Mohri"
Introduction: In atezolizumab plus bevacizumab (Atezo/Bev) combination treatment, both drugs act on the immune system. Previously, we reported that immunological changes after Atezo/Bev administration for unresectable hepatocellular carcinoma (uHCC) revealed significant alterations in interleukin (IL)-6, soluble IL-2 receptor, tumor necrosis factor-alpha, and programmed cell death-1 levels. Among these variable factors, serum levels of IL-6 can be easily measured on a commercial basis.
View Article and Find Full Text PDFArticle Synopsis
- Atezolizumab plus bevacizumab (AteBev) is a primary treatment for patients with unresectable hepatocellular carcinoma (uHCC), and this study investigates potential second-line therapies after unsuccessful AteBev treatment.
- The study included 60 uHCC patients who underwent imaging and blood tests before and after receiving AteBev, revealing a 31.7% overall response rate after six weeks.
- For those who subsequently received lenvatinib, the overall response rate improved to 45%, with notable changes in serum fiboblast growth factor-19 levels potentially indicative of treatment efficacy.
Article Synopsis
- Atezolizumab plus bevacizumab (AteBev) is a common first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC), and the study examines its effects on serum cytokines and immune reactions.
- The researchers analyzed blood samples from Japanese patients treated with AteBev, noting responses and changes in cytokine levels after treatment.
- The results showed that patients with partial response (PR) had increased levels of certain cytokines, while those with progressive disease (PD) had significant changes that suggest the need for improved T-cell activation against tumors in uHCC.
Introduction: Previously, we reported that the tyrosine kinase inhibitor (TKI) sorafenib decreases serum levels of carnitine and reduces skeletal muscle volume. Moreover, others reported that TKIs might lead to cardiomyopathy or heart failure. Therefore, this study aimed to evaluate the effects of lenvatinib (LEN) on skeletal muscle volume and cardiac function in patients with hepatocellular carcinoma (HCC).
View Article and Find Full Text PDFIntroduction: Atezolizumab, an immune checkpoint inhibitor, plus bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), is an approved first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Immune checkpoint inhibitors are more effective in patients with HCC when administered with anti-VEGF drugs; however, these drugs affect host immunity. Lenvatinib is an anti-VEGF agent used to treat HCC; therefore, this study evaluated the effect of treatment of HCC with lenvatinib on host immunity in patients with chronic liver disease (CLD).
View Article and Find Full Text PDFAdaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
Cancer Chemother Pharmacol
January 2022
Purpose: The aim of this study was to clarify the adaptation of lenvatinib treatment in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT).
Method: Fifty-three patients with HCC were treated with lenvatinib. Before and after treatment blood sampling, patients were examined by computed tomography and ultrasonography.